161 related articles for article (PubMed ID: 8463136)
1. Comparative studies on the metabolism of new fluorinated pyrimidine drugs in the liver by in vivo 19F magnetic resonance spectroscopic observation.
Harada M; Nishitani H; Koga K; Miura I; Kimura A
Jpn J Cancer Res; 1993 Feb; 84(2):197-202. PubMed ID: 8463136
[TBL] [Abstract][Full Text] [Related]
2. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
Tatsumi K; Yamauchi T; Kiyono K; Kishi K; Yanagihara Y; Imaoka T; Kawaguchi T; Kubo M
J Biochem; 1993 Dec; 114(6):912-8. PubMed ID: 8138551
[TBL] [Abstract][Full Text] [Related]
3. [BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Fujii S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2244-50. PubMed ID: 2955745
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of tegafur in rat liver observed by in vivo 19F magnetic resonance spectroscopy and chromatography.
Harada M; Nishitani H; Koga K; Miura I; Umeno Y
Jpn J Cancer Res; 1992 Apr; 83(4):387-91. PubMed ID: 1506273
[TBL] [Abstract][Full Text] [Related]
5. [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy].
Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):760-8. PubMed ID: 6424581
[TBL] [Abstract][Full Text] [Related]
6. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.
Tatsumi K; Fukushima M; Shirasaka T; Fujii S
Jpn J Cancer Res; 1987 Jul; 78(7):748-55. PubMed ID: 3114201
[TBL] [Abstract][Full Text] [Related]
8. Enzymes of uracil catabolism in normal and neoplastic human tissues.
Naguib FN; el Kouni MH; Cha S
Cancer Res; 1985 Nov; 45(11 Pt 1):5405-12. PubMed ID: 3931905
[TBL] [Abstract][Full Text] [Related]
9. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
[TBL] [Abstract][Full Text] [Related]
10. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.
Tuchman M; Ramnaraine ML; O'Dea RF
Cancer Res; 1985 Nov; 45(11 Pt 1):5553-6. PubMed ID: 4053028
[TBL] [Abstract][Full Text] [Related]
11. In vivo 19F NMR comparative study of 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and an FT-uracil coadministration system in mouse tumors.
Kanazawa Y; Kurogi S; Shinohara S; Noda Y; Masuda K
Chem Pharm Bull (Tokyo); 1994 Apr; 42(4):774-8. PubMed ID: 8020119
[TBL] [Abstract][Full Text] [Related]
12. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors].
Harada M; Nishitani H; Shirahama T; Koga K; Miura I
Gan To Kagaku Ryoho; 1991 Jan; 18(1):75-80. PubMed ID: 1899014
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Fujii S; Fukushima M; Shimamoto Y; Ohshimo H; Imaoka T; Shirasaka T
Jpn J Cancer Res; 1989 Feb; 80(2):173-81. PubMed ID: 2498252
[TBL] [Abstract][Full Text] [Related]
14. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
15. [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
Shirasaka T; Fukushima M; Shimamoto Y; Kimura Y; Ohshimo H; Imaoka T; Kimura A; Utsunomiya T; Fujii S
Gan To Kagaku Ryoho; 1990 May; 17(5):1051-8. PubMed ID: 2334171
[TBL] [Abstract][Full Text] [Related]
16. [Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice].
Okamoto M; Takao A; Fujita H
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3483-90. PubMed ID: 3789759
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
18. [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
Suenaga M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3313-8. PubMed ID: 2825604
[TBL] [Abstract][Full Text] [Related]
19. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism.
Davis LE; Lenkinski RE; Shinkwin MA; Kressel HY; Daly JM
Cancer; 1993 Dec; 72(12):3715-22. PubMed ID: 8252488
[TBL] [Abstract][Full Text] [Related]
20. Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay.
Traut TW; Loechel S
Biochemistry; 1984 May; 23(11):2533-9. PubMed ID: 6433973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
